ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Bioreducible Pro-drug Inhibitors of Enolase

preprint
submitted on 26.03.2020, 05:25 and posted on 26.03.2020, 10:28 by Victoria Yan, Kristine Yang, Elliot Ballato, Kenisha Arthur, Dimitra Georgiou, Florian Muller
Glycolysis inhibition remains aspirational in cancer therapy. We recently described a promising phosphonate inhibitor of Enolase for cancers harboring deletions in ENO1. Here, we describe the application of nitroheterocycle pro-drugs capitalizing on tumor hypoxia. These bioreducible pro-drugs exhibit up to 14-fold greater potency under hypoxic conditions compared to normoxia and exhibit robust stability in biological fluids. Our work provides strong proof-of-concept for using bioreduction as a pro-drug delivery strategy in the context of Enolase inhibition.

Funding

American Cancer Society

National Comprehensive Cancer Network

History

Email Address of Submitting Author

victoriacyanide@gmail.com

Institution

University of Texas MD Anderson Cancer Center

Country

USA

ORCID For Submitting Author

0000-0003-0837-5184

Declaration of Conflict of Interest

F.L.M., V.C.Y., K.L.Y., and E.S.B. are on a patent application describing second-generation pro-drug inhibitors of Enolase.

Exports

ChemRxiv

Exports